Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (3378)

Overview

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. is a China-based clinical-stage biotechnology company engaged in the discovery, development, and commercialization of innovative immunotherapies aimed at treating cancers and autoimmune diseases. Utilizing its proprietary VersatiBody platform, the company is advancing a diverse pipeline of therapeutic candidates in the field of immuno-oncology. The lead candidate, HX009, is a bifunctional anti-PD-1/SIRPα antibody fusion protein designed to enhance immune responses against tumors and is currently undergoing Phase 2 trials for advanced solid neoplasms. Established in 2014 and headquartered in Wuhan, Hanx Biopharmaceuticals is committed to driving the development of next-generation precision therapies within the global biotechnology sector.

Products and Services

• HX009: This is a bifunctional anti-PD-1/SIRPα antibody fusion protein that aims to boost the immune system's ability to fight tumors. Currently in Phase 2 trials, HX009 is designed to treat patients with advanced solid neoplasms by focusing on dual pathways to enhance antitumor efficacy.
• HX301: A multi-targeted kinase inhibitor that addresses a range of signaling pathways involved in tumor growth. By inhibiting specific kinases, HX301 seeks to slow down or halt tumor progression in patients.
• HX044: This bispecific antibody targets CD47 and CTLA4, specifically aimed at treating PD-1-resistant solid tumors. Currently in Phase 1/2 trials, HX044 works by exploiting two immune checkpoints to stimulate a stronger immune response against resistant tumors.
• HX008: A PD-1 antagonist monoclonal antibody designed to block the PD-1 pathway, which tumors often use to evade the immune system. By inhibiting this pathway, HX008 aims to reinvigorate the body’s natural immune response to cancer.

Focused on addressing important unmet medical needs in oncology and immunology, Hanx Biopharmaceuticals employs advanced techniques such as monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates in its product offerings.